SNO 2019 - Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Nov 20 - Nov 24, 2019 | PhoenixAZUS
LARVOL is not affiliated with Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 115 abstracts linked to Trials
Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL
Development of a novel class of cGAS agonists to trigger STING pathway-dependent innate immune responses against Glioblastoma
Response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutated glioblastoma: a case report
A phase I study of Suberoylanilide Hydroxamic Acid (SAHA) with Temsirolimus in children with newly diagnosed or progressive diffuse intrinsic pontine glioma (DIPG)
Delta-24-RGD oncolytic adenovirus mediates anti-tumor effect in localized and disseminated AT/RT murine models
Nivolumab vs bevacizumab in patients with recurrent glioblastoma: exploratory analysis of MGMT methylation status and baseline corticosteroid use
Entrectinib in children and adolescents with recurrent or refractory solid tumors including primary CNS tumors
Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG)
Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumors
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study
A Phase 2 trial of pembrolizumab and bevacizumab in melanoma brain met patients
Phase II study of palbociclib in brain metastases harboring CDK pathway alterations
Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumors
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase 2 GEOMETRY mono-1 study
A randomized, double-blind, placebo-controlled phase 3 trial of depatuxizumab mafodotin (ABT-414) in Epidermal Growth Factor Receptor (EGFR) amplified (amp) newly diagnosed glioblastoma (nGBM)